Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists
Symposium Chairs: T. Blum (Berlin, Germany), M. Wijsenbeek (Rotterdam, Netherlands)
Aims: to provide an overview of the epidemiology, clinical, radiological and pathological characteristics and prognosis of patients with lung cancer (LC) associated with fibrotic interstitial lung disease (fILD); to describe evidence of pathophysiological intersections between these two diseases and the importance of designing new therapeutic strategies based on this knowledge; to explain the importance of cancer treatments that could improve the survival of such patients; to investigate how anti-fibrotic treatments or other therapeutic innovations could modify the natural history of these diseases.